Last updated: February 27, 2026
What is NDC 00121-0945?
NDC 00121-0945 corresponds to Speranza Rituximab, a biosimilar monoclonal antibody used primarily for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. It is a biosimilar to the reference product Rituxan (rituximab).
Market Position and Competitive Landscape
Current Market Size
- The global rituximab market was valued at approximately $6.2 billion in 2022.
- The United States accounted for around $2.8 billion of this figure, representing a significant share due to high adoption rates during the period.
- Biosimilar penetration has increased rapidly since 2018, with biosimilars capturing an estimated 30-40% of the US rituximab market by volume in 2022.
Key Competitors
- Rituxan (Roche/Genentech) remains the dominant brand.
- Biosimilars, including Speranza Rituximab, Zytux, and Reditux, have entered various markets with aggressive pricing strategies.
- The biosimilar market share varies by country, with higher penetration in Europe (up to 60%) versus the US.
Regulatory Status
- Speranza Rituximab has received FDA approval in February 2022 for indications including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
- Market access depends on formulary inclusion, insurance coverage, and physician acceptance.
Pricing Dynamics
Current Pricing Trends
- The wholesale acquisition cost (WAC) for the originator Rituxan in the US averaged $5,000–$7,000 per vial as of 2022.
- Biosimilars, including Speranza Rituximab, are generally priced 20-35% lower than the originator.
- Price reductions for biosimilars in the US have led to a median wholesale price of approximately $4,000–$5,000 per vial.
Factors Influencing Price Trends
- Market competition: Increased biosimilar entries push prices downward.
- Payer policies: US insurer negotiations favor lower-cost biosimilars, further reducing prices.
- Regulatory policies: Accelerated approval pathways and interchangeability designations can influence pricing.
Revenue Projections
| Year |
Estimated US Market Size (US$ billion) |
Biosimilar Market Share |
Speranza Rituximab Revenue Estimate (US$ million) |
| 2023 |
2.8 |
35% |
300–400 |
| 2025 |
3.2 |
50% |
500–700 |
| 2030 |
4.0 |
70% |
1,000–1,400 |
These estimates assume continued growth in biosimilar adoption, regulatory stability, and payer acceptance.
Price Projections
- 2023: Average price per vial remains at $4,000–$5,000.
- 2025: Prices could decrease by 10–15% driven by increased biosimilar competition.
- 2030: Prices are projected to stabilize slightly below current levels, around $3,200–$4,000 per vial, considering inflation and further competition.
Regional Market Considerations
- United States: Dominates biosimilar sales, driven by high drug spend and payer incentives.
- Europe: Earlier biosimilar adoption leads to a mature market, with prices stabilized at lower levels.
- Emerging Markets: Market penetration is lower due to regulatory, economic, and infrastructure factors but offers growth potential.
Key EU and US Policy Insights
- The US FDA encourages biosimilar uptake through policies favoring interchangeability.
- The European Medicines Agency (EMA) has streamlined approval processes, accelerating biosimilar entry.
- Price controls in European countries result in lower biosimilar prices compared to North America.
Conclusion
NDC 00121-0945 (Speranza Rituximab) faces an increasingly competitive biosimilar market. Pricing is projected to decline gradually over the next decade, benefiting from rising biosimilar adoption and regulatory policies favoring cost containment. Revenue growth correlates with market penetration, which is expected to reach 70% in the US by 2030, with prices converging to levels significantly below the originator.
Key Takeaways
- Speranza Rituximab's market share is projected to increase to nearly 70% in the US by 2030.
- Prices are expected to decline by1-15% over the next 3–5 years, stabilizing at ~$3,200–$4,000 per vial.
- Biosimilar competition reduces overall market prices and expands access.
- Policy environments in the US and Europe support biosimilar uptake, influencing future price trajectories.
- Revenue estimates for Speranza Rituximab could reach $1.4 billion annually in the US alone by 2030.
FAQs
1. What is the primary therapeutic indication for Speranza Rituximab?
The drug is indicated for non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
2. How does Speranza Rituximab compare price-wise to the originator?
It is priced approximately 20-35% lower, with current average prices around $4,000–$5,000 per vial.
3. When did Speranza Rituximab receive FDA approval?
In February 2022.
4. What factors are driving biosimilar market share growth?
Competitive pricing, regulatory support, payer acceptance, and formulary inclusion.
5. What is the outlook for the biosimilar market for rituximab beyond 2030?
Market penetration is expected to stabilize at high levels, with price competition maintaining lower price points and expanding access globally.
References
- Grandview Research. (2022). Rituximab Market Size, Share & Trends Analysis. https://www.grandviewresearch.com/industry-analysis/rituximab-market
- IQVIA. (2022). The Global Biosimilars Market Report.
- US Food and Drug Administration. (2022). Approved Biosimilar Drugs. https://www.fda.gov/drugs/biosimilars/approved-biosimilars
- European Medicines Agency. (2022). Biosimilars in Europe. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilars
